Pharmaceutical giant AstraZeneca has suffered a fresh setback after pulling the plug on a late-stage lung cancer drug trial.
The FTSE 100 group revealed that its Volrustomig treatment, when combined with chemotherapy, was unlikely to increase survival rates for lung cancer patients compared to current standard options.